Gut microbiota-derived metabolite trimethylamine-N-oxide (TMAO) is emerging as a new potentially important cause of increased cardiovascular risk. The purpose of this meta-analysis was to systematically estimate and quantify the association between TMAO plasma levels, mortality, and major adverse cardio and cerebrovascular events (MACCE).
Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis / Schiattarella, G.G., Sannino, A., Toscano, E., Giugliano, G., Gargiulo, G., Franzone, A., Trimarco, B., Esposito, G., Perrino, C.. - In: EUROPEAN HEART JOURNAL. - ISSN 0195-668X. - 38:39(2017), pp. 2948-2956-2956. [10.1093/eurheartj/ehx342]
Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis
SCHIATTARELLA, GABRIELE GIACOMO;SANNINO, ANNA;GIUGLIANO, GIUSEPPE;GARGIULO, GIUSEPPE;FRANZONE, ANNA;TRIMARCO, BRUNO;ESPOSITO, GIOVANNI;PERRINO, CINZIA
2017
Abstract
Gut microbiota-derived metabolite trimethylamine-N-oxide (TMAO) is emerging as a new potentially important cause of increased cardiovascular risk. The purpose of this meta-analysis was to systematically estimate and quantify the association between TMAO plasma levels, mortality, and major adverse cardio and cerebrovascular events (MACCE).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
